<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145258</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12398</org_study_id>
    <secondary_id>EDCTP RIA2017T-2019</secondary_id>
    <nct_id>NCT04145258</nct_id>
  </id_info>
  <brief_title>Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis</brief_title>
  <acronym>INTENSE-TBM</acronym>
  <official_title>Intensified Tuberculosis Treatment to Reduce the Mortality of HIV-infected and Uninfected Patients With Tuberculosis Meningitis: a Phase III Randomized Controlled Trial (Acronym: INTENSE-TBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan
      superiority trial assessing the efficacity of two interventions to reduce mortality from
      tuberculous meningitis (TBM) in adolescents and adults with or without HIV-infection in
      sub-Saharan Africa:

        -  Intensified TBM treatment with high-dose rifampicin and linezolid, compared to WHO
           standard TBM treatment.

        -  Aspirin, compared to not receiving aspirin. The trial will be open-label for anti-TB
           treatment and placebo-controlled for aspirin treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Settings: CÃ´te d'Ivoire, Madagascar, Uganda, South Africa.

      Follow-up: Participants will be followed up for 40 weeks.

      Sample size: 768 patients (192 in each arm).

      Primary analysis: We will use a Cox proportional hazard ratio model to compare intensified TB
      treatment with WHO standard TB treatment, and aspirin with placebo, adjusting for the initial
      stratification variables (trial country, HIV status, British Medical Research Council |BMRC]
      severity grade). The primary analysis will be conducted in the intention to treat population.

      Sub-studies:

        -  The PK-PD sub-study will take place in the 4 participating countries, and involve 40
           participants in total.

        -  The Multi-Omics sub-study will only take place in South-Africa. It will involve 160
           participants in this country.

      Participants in each sub-study will sign a specific informed consent.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The trial will be open-label for anti-TB treatment and placebo-controlled for aspirin treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of all-cause death</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause death</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause death or loss to follow-up</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of new central neurological event or aggravation of a central neurological event existing at baseline</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of grade 3-4 adverse events (DAIDS adverse events grading table)</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of serious adverse events</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of solicited treatment related adverse events</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with disability</measure>
    <time_frame>40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>M. tuberculosis culture conversion rate</measure>
    <time_frame>1 week and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to culture positivity</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first hospital discharge</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness incremental ratio of trial interventions</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of resistance to anti-TB drugs among patients with positive culture at inclusion</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of patients: In vitro bactericidal activity of anti-TBM treatment</measure>
    <time_frame>1 week and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of patients: Maximum Plasma Concentration [Cmax] of rifampicin and linezolid</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma Cmax, cerebrospinal fluid [CSF] Cmax, and plasma/CSF Cmax ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of patients: Minimum Plasma Concentration [Cmin] of rifampicin and linezolid</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma Cmin, cerebrospinal fluid [CSF] Cmin, and plasma/CSF Cmin ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of patients: Area Under the Curve [AUC] of rifampicin and linezolid</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma AUC, cerebrospinal fluid [CSF] AUC, and plasma/CSF AUC ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of patients: Time for maximal concentration [Tmax] of rifampicin and linezolid</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma Tmax, cerebrospinal fluid [CSF] Tmax, and plasma/CSF Tmax ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of patients: Half-life (t1/2) of rifampicin and linezolid</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma t1/2, cerebrospinal fluid [CSF] t1/2, and plasma/CSF t1/2 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants: Rate of new AIDS-defining illnesses</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants: Percentage of participants with virological success (plasma HIV-1 RNA &lt;50 copies/ml)</measure>
    <time_frame>28 weeks and 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants: CD4 count change from baseline</measure>
    <time_frame>28 weeks and 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants, subset of patients: Maximum Plasma Concentration [Cmax] of of dolutegravir</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma Cmax, cerebrospinal fluid [CSF] Cmax, and plasma/CSF Cmax ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants, subset of patients: Minimum Plasma Concentration [Cmin] of dolutegravir</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma Cmin, cerebrospinal fluid [CSF] Cmin, and plasma/CSF Cmin ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants, subset of patients: Area Under the Curve [AUC] of dolutegravir</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma AUC, cerebrospinal fluid [CSF] AUC, and plasma /CSF AUC ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants, subset of patients: Time for maximal concentration [Tmax] of dolutegravir</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma Tmax, cerebrospinal fluid [CSF] Tmax, and plasma /CSF Tmax ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants, subset of patients: Half-life (t1/2) of dolutegravir</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma t1/2, cerebrospinal fluid [CSF] t1/2, and plasma/CSF t1/2 ratio</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">768</enrollment>
  <condition>Tuberculous Meningitis</condition>
  <arm_group>
    <arm_group_label>WHO TBM treatment + placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin
W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WHO TBM treatment + aspirin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d
W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensified TBM treatment + placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin
W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensified TBM treatment + aspirin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d
W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)</description>
    <arm_group_label>Intensified TBM treatment + aspirin</arm_group_label>
    <arm_group_label>WHO TBM treatment + aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of aspirin</intervention_name>
    <description>Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)</description>
    <arm_group_label>Intensified TBM treatment + placebo</arm_group_label>
    <arm_group_label>WHO TBM treatment + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WHO TBM treatment</intervention_name>
    <description>2 months of (R-H-Z-E) + 7 months of (R-H)</description>
    <arm_group_label>WHO TBM treatment + aspirin</arm_group_label>
    <arm_group_label>WHO TBM treatment + placebo</arm_group_label>
    <other_name>Standard WHO treatment for TB meningitis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensified TBM treatment</intervention_name>
    <description>2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid</description>
    <arm_group_label>Intensified TBM treatment + aspirin</arm_group_label>
    <arm_group_label>Intensified TBM treatment + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age â¥ 15 years

          2. TBM defined as &quot;definite&quot;, &quot;probable&quot; or &quot;possible&quot;

          3. Signed Informed Consent

               -  Definite TBM = at least one of the following criteria: acid-fast bacilli seen in
                  CSF microscopy, positive CSF M. tuberculosis culture, or positive CSF M.
                  tuberculosis commercial nucleic acid amplification test.

               -  Probable TBM = total modified Marais score â¥12 when neuroimaging is available, or
                  â¥10 when neuroimaging is not available (at least 2 points should come from CSF or
                  cerebral imaging criteria).

               -  Possible TBM = total modified Marais 6-11 when neuroimaging is available, or 6-9
                  when neuroimaging is not available.

        Exclusion criteria:

          -  &gt; 5 days of TB treatment

          -  Renal failure (eGFR&lt;30 ml/min, CKD-EPI formula).

          -  Neutrophil count &lt; 0.6 x 109/L.

          -  Hemoglobin concentration &lt; 8 g/dL.

          -  Platelet count &lt; 50 x 109/L.

          -  Total bilirubin &gt; 2.6 times the Upper Limit of Normal.

          -  ALT &gt; 5 times the Upper Limit of Normal.

          -  Clinical evidence of liver failure or decompensated cirrhosis.

          -  For women: more than 17 weeks pregnancy or breastfeeding.

          -  For patients without decrease level of consciousness (Glasgow Coma Scale = 15):
             Peripheral neuropathy scoring Grade 3 or above on the Brief Peripheral Neuropathy
             Score (BPNS).

          -  Documented M. tuberculosis resistance to rifampicin.

          -  Positive gram-stain, bacterial culture or cryptococcal antigen in the Cerebral Spinal
             Fluid.

          -  Evidence of active bleeding (hemoptysis, gastrointestinal bleeding, hematuria,
             intracranial bleeding).

          -  Inability to collect Cerebral Spinal Fluid, except for patients with confirmed
             tuberculosis (by rapid molecular test or culture) from another biological sample and
             clinical and/or CT scan evidence of meningitis.

          -  Major surgery within the last two weeks prior to inclusion.

          -  Ongoing chronic aspirin treatment (eg for cardiovascular risk).

          -  Current use of drugs contraindicated with study drugs and that cannot be safely
             stopped (see Appendix 1: Drugs contra-indicated with study drugs).

          -  In available history from patients:

               -  Evidence of past intracranial bleeding.

               -  Evidence of past of peptic ulceration.

               -  Evidence of recent (&lt; 3 month) gastrointestinal bleeding.

               -  Known hypersensitivity contraindicating the use of study drugs .

               -  Evidence of porphyria.

               -  Evidence of hyperuricemia or gout.

          -  Any reason which at the discretion of the investigator would compromise safety and
             cooperation in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice Bonnet, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice Bonnet, M.D., Ph.D.</last_name>
    <phone>+33 (0)5 56 79 58 26</phone>
    <email>fabrice.bonnet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xavier Anglaret, M.D., Ph.D.</last_name>
    <phone>+33 (0)5 57 57 12 58</phone>
    <email>xavier.anglaret@u-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cocody University Hospital</name>
      <address>
        <city>Abidjan</city>
        <country>CÃ´te D'Ivoire</country>
      </address>
    </facility>
    <contact>
      <last_name>Horo Kigninlman, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Treichville University Hospital</name>
      <address>
        <city>Abidjan</city>
        <country>CÃ´te D'Ivoire</country>
      </address>
    </facility>
    <contact>
      <last_name>GisÃ¨le Kouakou, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yopougon University Hospital</name>
      <address>
        <city>Abidjan</city>
        <country>CÃ´te D'Ivoire</country>
      </address>
    </facility>
    <contact>
      <last_name>Thierry Odehoury-Koudou, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Joseph Raseta Befelatanana</name>
      <address>
        <city>Antananarivo</city>
        <country>Madagascar</country>
      </address>
    </facility>
    <contact>
      <last_name>Mamy Jean de Dieu Randria, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Tambohobe</name>
      <address>
        <city>Fianarantsoa</city>
        <country>Madagascar</country>
      </address>
    </facility>
    <contact>
      <last_name>Rivonirina Andry Rakotoarivelo, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Morafeno</name>
      <address>
        <city>Toamasina</city>
        <country>Madagascar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert J Wilkinson, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mitchells Plain Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Graeme Meintjes, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Somerset Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Sean Wassermann, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dora Nginza Hospital</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Livingstone and PE Central Hospitals</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>John Black, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mbarara Regional Reference Hospital</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Reference Hospital of Kabale</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
    <contact>
      <last_name>Marion Namutebi, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>CÃ´te D'Ivoire</country>
    <country>Madagascar</country>
    <country>South Africa</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculous Meningitis</keyword>
  <keyword>Intensified treatment</keyword>
  <keyword>High dose Rifampicin</keyword>
  <keyword>Linezolid</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Subsaharan Africa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Tuberculosis, Meningeal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

